Dr. Evgenii Shumilov - Oncology and Hematology - Outstanding Scientist Award

University Hospital Münster Medical Clinic A - Germany

Author Profile

🎓 Early academic pursuits

Dr. Evgenii Shumilov began his academic journey in kirovskaya gebiet, russland, where he completed his general secondary education in june 2006. driven by a passion for human biology and clinical care, he enrolled in the staatliche medizinische akademie in kirow in 2006. the following year, he transitioned to the esteemed st. petersburger staatliche medizinische universität i.p. pawlow, where he pursued his degree in human medicine until 2012. during this formative period, he developed a growing interest in the biochemical pathways influencing addiction, which would later shape his doctoral research.

🏥 Professional endeavors

His professional career started immediately after his graduation with a clinical internship in internal medicine at the universitätsklinikum st. petersburg i.p. pawlow. dr. shumilov then completed a specialized clinical training in oncology at the renowned n.n. petrow institute for oncology. from 2015 to 2021, he continued his facharztausbildung (specialist training) in internal medicine, hematology, and oncology at the universitätsmedizin göttingen. since 2021, he has served in various capacities at the universitätsklinikum münster, advancing to oberarzt (senior physician) in the day clinic of oncology by 2022. his role requires the coordination of clinical therapies, implementation of modern diagnostics, and integration of interdisciplinary care — akin to the precision and optimization seen in power electronics systems.

🔬 Contributions and research focus

Dr. Shumilov has made significant scientific contributions in the field of pharmacology and hemato-oncology. between 2012 and 2015, he pursued a doctoral program in pharmacology at the anichkow institute for experimental medicine, focusing on neuropharmacology and the role of orexin-1 receptors in addiction — a study that mirrors the regulatory mechanisms of feedback and control in power electronics. in 2018, he earned a second doctorate (dr. med.) from the university of bern, switzerland, with a dissertation exploring genetic mutations bridging Oncology and Hematology hematopoietic lineages and solid tumors in the age of high-throughput sequencing. his work has helped redefine diagnostic paradigms in clinical oncology.

🌍 Impact and influence

Dr. Shumilov’s cross-disciplinary expertise bridges clinical practice and molecular diagnostics. his innovative thinking, reflected in his dual doctoral research and international academic Oncology and Hematology exposure, positions him as a leader in precision medicine. like the transformative role of power electronics in renewable energy systems, his influence lies in optimizing diagnostic accuracy and tailoring therapies for oncology patients. he is actively mentoring junior clinicians, integrating translational research into routine care, and contributing to academic networks across europe and russia.

📚 Academic citations and recognitions

He has received notable academic recognition, including a posterpreis at the dgho annual meeting in stuttgart (2017), and the prestigious dfg “clinician scientist” funding from 2020 to 2021. his scientific contributions are frequently cited in studies on neuropharmacology and next-generation sequencing diagnostics. his work on orexin receptors and hematologic malignancies Oncology and Hematology continues to influence both pharmacologic models and clinical protocols.

🌱 Legacy and future contributions

Dr. Shumilov’s legacy lies in his capacity to interweave basic science with clinical oncology. he is currently leading projects that integrate high-throughput genomic data with patient-specific therapy plans, aiming for breakthroughs in hematologic and solid tumor treatments. with a forward-looking perspective, he is exploring digital integration and ai-assisted diagnostics, similar to how power electronics revolutionize control in automated systems. his future vision includes strengthening international research collaborations and expanding educational programs for medical scientists.

Notable Publications

Title: Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
Author(s): Evgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, Paolo Mazzeo, Rebecca Wurm-Kuczera, Vladan Vucinic, Udo Holtick, Hristo Boyadzhiev, Thomas Melchardt, Alexander Sebastian Hölscher, et al.
Journal: Blood Advances
Title: Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning
Author(s): Evgenii Shumilov, Lena Levien, Paolo Mazzeo, Wolfram Jung, Andreas Leha, Raphael Koch, Justin Hasenkamp, Gerald Wulf
Journal: Leukemia & Lymphoma
Title: Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study
Author(s): Evgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, Meng Wang, Thomas Melchardt, Udo Holtick, Ulrike Bacher, Philipp B. Staber, Paolo Mazzeo, Corinna Leng, et al.
Journal: Blood Advances
Title: Benefit of repeated COVID‐19 vaccination for patients with B‐cell malignancies
Author(s): Ulrike Bacher, Evgenii Shumilov, Thomas Pabst
Journal: British Journal of Haematology
Title: Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma—A Critical Toxicity Evaluation in the Modern Treatment Era
Author(s): Michael Oertel, Tom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, Anne Bremer, Stephan Rehn, Georg Lenz, Cyrus Khandanpour, Hans Theodor Eich
Journal: Cancers

Early academic pursuits 🎓

Mingqian fang embarked on his academic journey with a keen interest in biology and medical sciences, eventually specializing in the study of disease pathogenesis. his early work centered on understanding how infections and inflammatory responses influence mental health, particularly focusing on stress-induced depression. his educational background laid a strong foundation for his future research in both neuroscience and cardiovascular diseases. as a professor at the kunming institute of zoology, chinese academy of sciences, he has consistently contributed to groundbreaking research.

Professional endeavors 🏢

As a professor at the kunming institute of zoology, mingqian has dedicated his career to exploring the connections between stress, depression, and physiological responses to infections. his research has not only deepened our understanding of how stress exacerbates mental health disorders, but has also opened pathways to developing effective treatments for both depression and cardiovascular diseases. his expertise extends to studying natural toxin peptides, with particular focus on their biomedical applications.

Contributions and research focus 🔬

Mingqian’s primary research areas include the pathogenesis of diseases like depression under stressful stimuli, such as infections and inflammation, and the Immunology & Hematology development of innovative drugs to treat these conditions. his notable work includes the discovery of how lipopolysaccharide-binding protein expression is increased by stress, promoting depressive symptoms by inhibiting monoamine synthesis. he has also explored the role of bat-derived peptides and how they impact neuroinflammation, contributing significantly to the understanding of the body's immune response to various stressors.

Accolades and recognition 🏅

Mingqian fang’s research has been widely recognized in the scientific community, with publications in high-impact journals such as immunity and pnas. his works have earned accolades due to their novel insights into how biological systems respond to stress and disease. his research in immune responses and toxin peptides has Immunology & Hematology been acknowledged globally, with his papers being published in top-tier journals with high impact factors, demonstrating the importance and quality of his findings.

Impact and influence 🌍

Mingqian’s research has had a far-reaching impact on both neuroscience and cardiovascular medicine. by linking mental health issues like depression to biological processes such as inflammation, he has paved the way for new treatment methodologies. his work on natural toxins also holds promise for creating innovative drugs Immunology & Hematology that could target specific disease mechanisms, further influencing the pharmaceutical industry and biomedical research. his influence spans across multiple fields, combining neuroscience, immunology, and pharmacology.

Legacy and future contributions 🔮

Mingqian fang’s ongoing work ensures that his legacy in the scientific world continues to grow. his pioneering research on stress-related depression and cardiovascular conditions is laying the groundwork for future innovations in drug development. by bridging the gap between neuroscience and immunology, his research will likely inspire further interdisciplinary studies aimed at improving human health. his work on bat-derived peptides, in particular, opens exciting possibilities for novel therapies.

Notable Publications

Title: The Price of P2X7R Freedom is Neuroinflammation
Authors: Fang M, Lai R
Journal: Immunity
Date: March 2024
DOI: 10.1016/j.immuni.2024.02.009

Title: Transferrin Is Up-Regulated by Microbes and Acts as a Negative Regulator of Immunity to Induce Intestinal Immunotolerance
Authors: Tang X, Fang M, Cheng R, Niu J, Huang X, Xu K, Wang G, Sun Y, Liao Z, Zhang Z et al.
Journal: Research (Washington, D.C.)
Date: January 2024
DOI: 10.34133/research.0301

Title: Lipopolysaccharide-Binding Protein Expression is Increased by Stress and Inhibits Monoamine Synthesis to Promote Depressive Symptoms
Authors: Fang M, Li Y, Liao Z, Wang G, Cao Q, Li Y, Duan Y, Han Y, Deng X, Wu F et al.
Journal: Immunity
Date: February 2023
DOI: 10.1016/j.immuni.2023.02.002

Title: An Undefined Cystatin CsCPI1 from Tea Plant Camellia sinensis Harbors Antithrombotic Activity
Authors: Fang M, Cha JH, Wang HC, Ye P, Chen B, Chen M, Yang WH, Yan X
Journal: Biomedicine & Pharmacotherapy
Date: January 2023
DOI: 10.1016/j.biopha.2023.114285

Title: Hypoxia and Low Temperature Upregulate Transferrin to Induce Hypercoagulability at High Altitude
Authors: Li M, Tang X, Liao Z, Shen C, Cheng R, Fang M, Wang G, Li Y, Tang S, Xie L et al.
Journal: Blood
Date: November 2022
DOI: 10.1182/blood.2022016410